A phase 2, open-label study of S-6810 in patients with mycosis fungoides or Sezary syndrome

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221783

Enrollment

Registered

2012-05-10

Start date

2012-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycosis fungoides or Sezary syndrome

Interventions

investigational material(s) Generic name etc : S-6810 INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Main inclusion criteria 1. Patients with mycosis fungoides or Sezary syndrome confirmed by cutaneous symptom, histopathological diagnosis or hematological evidence 2. Patients whose TNMB staging criterion is T1-4N0-2M0B0-2 and meet any of the following: a) untreated mycosis fungoides/Sezary syndrome b) at least 4 weeks after treatment for mycosis fungoides/Sezary syndrome c) the effect of topical steroid, topical vitamin D3 derivatives, or ultraviolet therapy for mycosis fungoides/Sezary syndrome is stable or progressive within 4 weeks 3. Patients whose ECOG performance status is grade 0-2

Exclusion criteria

Exclusion criteria: Main exclusion criteria: Patients whose visceral metastasis was found by imaging evaluation within 4 weeks prior to enrollment

Design outcomes

Primary

Measure	Time frame
Efficacy (response rate)	—

Secondary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026